Feature | November 14, 2013

Mayo Clinic Studying Genomics of Antiplatelet Heart Medication

Participant DNA biobank to help elucidate genomics of coronary artery disease

November 14, 2013 — Professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration’s (FDA’s) recent recommendation that patients undergo genetic testing before taking Plavix (clopidogrel bisulfate).
 
The Tailored Antiplatelet Therapy to Lessen Outcomes after Percutaneous Coronary Intervention (TAILOR-PCI) study, launched this summer by the Center for Individualized Medicine and the Division of Cardiovascular Diseases at Mayo Clinic, examines whether prescribing heart medication based on a patient’s CYP2C19 genotype will help prevent heart attack, stroke, unstable angina and cardiovascular death in patients who undergo angioplasty.
 
“The current standard of care after angioplasty is to prescribe clopidogrel for one year, regardless of a person’s individual genotype, even though we have known for several years that variation in the CYP2C19 gene may diminish the benefit from the drug,” said Pereira, M.D., cardiologist, Mayo Clinic and principal investigator of TAILOR-PCI. “What we don’t know — and why there is such confusion in the cardiovascular community — is how these genetic changes affect long-term clinical outcomes and whether we can decrease overall health care costs.”
 
Plavix remains ineffective until the liver enzyme CYP2C19 metabolizes the drug into its active form. Some alternative medications, including Brilinta (ticagrelor), do not require activation through the same genetic pathway.
 
“Ticagrelor has its own risks, including serious or life-threatening bleeding,” said Pereira. “Additionally, this alternative therapy costs approximately six to eight times as much and must be taken twice a day. Ultimately, what we’re trying to do with TAILOR is use pharmacogenomics to determine whether choosing medication based on individual genotype will help patients live longer and whether the benefits will outweigh the risks of alternative therapies.”
 
Nilay Shah, Ph.D., associate professor of health services research, Mayo Clinic Health Sciences, will study potential cost impacts to the health care system.
 
“This study examines as much as an $8 billion question in health care,” said Shah. “Clopidogrel is the second-most prescribed medication in the United States, and although ticagrelor costs much more, the costs of taking patients into the emergency room and performing a second angioplasty are much higher.”
 
Another additional benefit of the study will be creation of a coronary artery disease (CAD) biobank containing DNA samples from the study’s 5,300 participants. Researchers at Mayo Clinic and elsewhere can mine these samples and use genomic sequencing technologies to help further medicine’s understanding of the origins of and risk factors for coronary heart disease.
 
“TAILOR-PCI is exactly the type of research we do every day — the kind that translates into better health for our patients and improves the delivery of care for millions of patients around the world,” said Gianrico Farrugia, M.D., director, May Clinic Center for Individualized Medicine.
 
Up to one-third of patients currently taking Plavix (up to half of some Asian populations) have a genomic variant implicated in diminished drug response. Study teams at 15 hospitals in three countries have teamed up to enroll 5,300 patients into TAILOR-PCI and deliver results in three years. The Pharmacogenomics Program in the Center for Individualized Medicine administers this study.
 
For more information: www.mayoclinic.com, www.mayoresearch.mayo.edu

Related Content

European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

Boston Scientific's Eluvia drug-eluting vascular stent system. Image courtesy of Boston Scientific.

Feature | Stents| July 31, 2015
According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents...
Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
Hansen Medical, Magellan 10 French Robotic Catheter, FDA 510(k) clearance
Technology | Robotic Systems| July 29, 2015
The Magellan 10 French Robotic Catheter from Hansen Medical is indicated for use in the peripheral vasculature.
MSCs, stem cells, end-stageheart failure, retrograde, coronary sinus,
News | Stem Cell Therapies| July 29, 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus...
Products | Guidewires| July 28, 2015
The Safari2 Pre-Shaped Guidewire.
CSI, ViperWire Advance Peripheral Guide Wire with Flex Tip, Stealth, Diamondback

Diamondback 360 Peripheral OAS image courtesy of Cardiovascular Systems Inc.

Technology | Atherectomy Devices| July 22, 2015
Cardiovascular Systems Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for its...
heart failure, Adaptive CRT trial, AdaptivCRT algorithm, readmissions
News | Heart Failure| July 22, 2015
Heart failure patients had a significantly lower chance of being readmitted within 30 days of discharge when treated...
Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA
News | Heart Valve Repair| July 22, 2015
Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
The Medicines Company, bivalirudin, Angiomax, litigation, Hospira Inc.
News | Cath Lab| July 22, 2015
The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the company...
Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
News | Antiplatelet and Anticoagulation Therapies| July 21, 2015
Two companion papers published in Academic Emergency Medicine  address the question of when it is appropriate to...
Overlay Init